Healthcare Stock Spotlight: Earnings Reports on Deck

Steris Corp (NYSE:STE) will unveil its latest earnings on Tuesday, May 8, 2012.  The average analyst estimate is for profit of 60 cents per share, a decline of 1.6% from the company’s actual earnings for the year-ago quarter. During the past three months, the average estimate has moved down from 64 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at 60 cents during the last month. Analysts are projecting profit to rise by 1.4% compared to last year’s $2.16.

The company enters this earnings report having missed estimates the last four quarters. Last quarter, the company fell short of expectations by 2 cents, reporting net income of of 59 cents per share against a mean estimate of profit of 61 cents per share. On average, analysts predict $380.4 million in revenue this quarter, a rise of 0.7% from the year-ago quarter. Analysts are forecasting total revenue of $1.39 billion for the year, a rise of 14.9% from last year’s revenue of $1.21 billion.

Tenet Healthcare Corp (NYSE:THC) will unveil its latest earnings on Tuesday, May 8, 2012. The average estimate of analysts is for net income of 9 cents per share, a decline of 43.8% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 19 cents. Between one and three months ago, the average estimate moved down. It has risen from 8 cents during the last month. Analysts are projecting profit to rise by 1.9% versus last year to 53 cents.

Last quarter, the company fell short of estimates by 3 cents, coming in at profit of 10 cents per share against a mean estimate of net income of 13 cents. The company topped expectations in the third quarter of the last fiscal year. Analysts are projecting a decline of 1.2% in revenue from the year-earlier quarter to $2.48 billion.

Insmed Inc. (NASDAQ:INSM) will unveil its latest earnings on Tuesday, May 8, 2012. The average estimate of analysts is for net loss of 34 cents per share, a narrower loss from the year-earlier quarter net loss of 37 cents. During the past three months, the average estimate has moved up from a loss of 38 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at a loss of 34 cents during the last month.

Last quarter, the company topped expectations by 10 cents, coming in at a loss of 28 cents per share versus a mean estimate of net loss of 38 cents per share. This followed two straight quarters of missing estimates. In the fourth quarter of the last fiscal year, the company’s loss widened to a loss of a $8.2 million (29 cents a share) from a loss of $5.8 million (49 cents) a year earlier, but beat analyst expectations. Revenue rose 6.2% to $1.4 million from $1.3 million.

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) will unveil its latest earnings on Tuesday, May 8, 2012. The average estimate of analysts is for profit of 86 cents per share, a rise of 65.4% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 94 cents. Between one and three months ago, the average estimate moved down. It also has dropped from 89 cents during the last month. For the year, analysts are projecting net income of $3.91 per share, a rise of 24.9% from last year.

Last quarter, the company missed estimates by 5 cents, coming in at profit of 96 cents per share versus a mean estimate of net income of $1.01 per share. In the third quarter of the last fiscal year, the company beat estimates by 3 cents. On average, analysts predict $102.5 million in revenue this quarter, a rise of more than twofold from the year-ago quarter. Analysts are forecasting total revenue of $489.2 million for the year, a rise of 79.7% from last year’s revenue of $272.3 million.

 

More from The Cheat Sheet